Progresif Multifokal Lökoensefalopati

Kartau, Marge, et al. "Progressive multifocal leukoencephalopathy: current insights." Degenerative neurological and neuromuscular disease (2019): 109-121.

Iacobaeus E, Burkill S, Bahmanyar S, et al. The national incidence of PML in Sweden, 1988–2013. Neurology. 2018;90: e498–e506. doi:10.1212/WNL.0000000000004926

Kartau M, Verkkoniemi-Ahola A, Paetau A, et al. The incidence and predisposing factors of John Cunningham virus-induced progressive multifocal leukoencephalopathy in Southern Finland: a population-based study. Open Forum Infect Dis. 2019; 6:2. doi:10.1093/ofid/ofz024

Berger JR, Pall L, Lanska D. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:1.doi:10.3109/13550289809113482

Blankenbach K, Schwab N, Hofner B, Adams O, KellerStanislawski B, Warnke C. Natalizumab-associated progressive multifocal leukoencephalopathy in Germany. Neurology. 2019;92:19. doi:10.1212/WNL.0000000000007451

Prosperini L, Scarpazza C, Imberti L, Cordioli C, De Rossi N, Capra R. Age as a risk factor for early onset of natalizumab-related progressive multifocal leukoencephalopath J Neurovirol. 2017;23:5. doi:10.1007/s13365-017-0561-9

Swinnen, Bart, et al. "Predictive value of JC virus PCR in cerebrospinal fluid in the diagnosis of PML." Diagnostic Microbiology and Infectious Disease 95.3 (2019): 114859.

Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy: a 25-year retrospective cohort study. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e618. doi: 10.1212/NXI.0000000000000618.

Prezioso, Carla, et al. "Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?." Multiple Sclerosis and Related Disorders 41 (2020): 102008.